The aim of our study was to develop a completely scaffold-free, viable, contractile cardiac tissue capable of being grafted into the damaged native heart. METHODS: Our technology is based on the fundamental characteristics of the self-assembling nature of cells. We created contractile cardiac spheroids by plating a mixture of rat neonatal ventricular cardiomyocytes, human dermal fibroblasts, and human coronary microartery endothelial cells in ultralow attachment plates. First, the optimal cell ratios for the 3 cell sources were determined. Next, approximately 1 Â 10 4 optimal spheroids were fused into a patch-like construct, and the morphologic characteristics and mechanical functions of these patches were evaluated. Finally, the cardiac patches were grafted into the hearts of F344 nude rats, and histologic studies were performed after transplantation. RESULTS: Synchronous beating of the cardiac patch was confirmed electrophysiologically and mechanically. A micronetwork of endothelial cells was also demonstrated in the construct, and the histologic study performed 5 days after transplantation showed the grafts to be viable, with functioning microvascular structures inside the graft tissue. CONCLUSIONS: We consider the application of our scaffold-free 3-dimensional tissue engineering technology to cardiac regeneration therapy is feasible and expect that this technology will become a promising tool for the treatment of end-stage heart failure.
Heart failure is one of the leading causes of death worldwide. The number of patients with end-stage heart failure has been increasing in recent years, despite the variety of mechanical and surgical strategies currently available. 1 Although the standard therapy for end-stage heart failure is considered to be heart transplantation, the severe shortage of donors limits the wide applicability of this procedure, and the need for immunosuppression impairs the patient's quality of life. 2 Similarly, although surgical interventions, such as the implantation of mechanical ventricular assist devices, are making progress, these interventions can only be applied in a limited number of patients and are associated with immense medical costs. 3 Therefore, the development of a novel strategy to resolve these issues is awaited.
Cellular cardiomyoplasty, a technique involving the injection of multipotential cells into the myocardium, was recently developed as an alternative therapeutic strategy for heart failure. Several studies of cardiomyoplasty using various cell sources have successfully demonstrated improved function of the damaged heart and subsequent regeneration of new myocardium. 4 However, significant problems are associated with cellular cardiomyoplasty due to the low retention rate, poor nutritional supply in the tissue, and lack of a proper anchoring matrix. 5 Hence, the creation of an acceptive cell environment is a central issue in the need to improve the effectiveness of cellular cardiomyoplasty.
To address the limitations of cellular cardiomyoplasty, a tissue engineering approach was developed to provide alternatives. The general strategy for cardiac tissue engineering is to combine cells suitable for cardiac therapy with a 3-dimensional (3-D) scaffold. There are currently various approaches for cardiac tissue engineering, such as the in situ delivery of cells with injectable biomaterials and in vitro engineering of contractile tissue constructs, followed by in vivo implantation. 6, 7 These scaffold-based tissue-engineering approaches also have several disadvantages, however. Notably, collagen and other biologic molecules are known to be immunogenic, 7 and the mechanical properties of biologic scaffolds do not mimic those of the native myocardium; hence, the scaffold rapidly degrades. 7 Further studies are thus needed to generate proper tissue engineering and/or cell delivery technologies.
To develop safe and effective procedures for cardiac cell and tissue transplantation, we focused on scaffold-free biofabrication technology using "spheroid formation." Spheroid formation is a well-known phenomenon associated with all culture processes, and spheroids possess several advantageous features for cardiac tissue engineering. 8 For example, the scaffold-free spheroid has a 3-D structure that may provide a rich extracellular matrix that is more relevant to the cardiac environment. Furthermore, spheroids can be assembled to form certain morphologies. We herein report a novel scaffold-free cardiac tissue engineering technique that yields functional and vascularized cardiac tissue that can be successfully transplanted into the nude rat heart.
Methods
This study conformed to the Guidelines for the Care and Use of Laboratory Animals (U.S. National Institutes of Health Publication No. 85-23, revised 1996) and the protocols of the Institutional Animal Care and Use Committee of Saga University.
Experimental protocol
A schematic representation of our experimental protocol is shown in Figure 1 . Preliminary experiments were first performed to determine the optimal cell ratios for the 3 cell sources (cardiomyocytes, endothelial cells, and fibroblasts) used to make the cardiac spheroids. Generated optimal spheroids were subsequently assembled to create cardiac patches, and the mechanical properties of these constructs were studied. Finally, the patches were transplanted into nude rats, and histologic studies were used to examine the tissues.
Figure 1
A schematic diagram of our spheroid-based scaffold-free cardiac tissue engineering strategy. HCMECs, human cardiac microvascular endothelial cells; RNVCMs, rat neonatal ventricular cardiomyocytes; HNDFBs, human normal dermal fibroblasts.
Primary culture of cardiomyocytes from the neonatal rat ventricle and human coronary endothelial cells and normal human dermal fibroblast culture Primary rat neonatal ventricular cardiomyocytes (RNVCMs) were prepared according to previously published procedures, with some modifications. 9 Human cardiac microvascular endothelial cells (HCMEC) were purchased from Cosmo-Bio (Tokyo, Japan) and were cultured in endothelial cell medium in dishes coated with type I collagen. Human normal dermal fibroblasts (HNDFBs) were purchased from Lonza Walkersville Inc and suspended in Dulbecco modified Eagle medium (Wako Pure Chemical Industries, Ltd, Osaka, Japan) containing 10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO), and 1% penicillin-streptomycin solution. The HCMECs and HNDFBs were maintained in a humidified 371C, 5% CO 2 incubator and passaged every 3 days until the required numbers of cells was obtained.
Fabrication of cardiac spheroids (cell aggregates)
Isolated primary RNVCMs and suspended HCMECs and HNDFBs were mixed at the ratios shown in Figure 2 , and the mixed cell suspensions were plated into ultralow attachment 96 U-well plates (Sumitomo Bakelite, Tokyo Japan) to form cardiac spheroids. The spheroids were maintained in a humidified atmosphere at 371C in a 5% CO 2 incubator, and the culture medium was changed every 2 days. The spheroid analysis used 1 to 2.5 Â 10 3 cardiomyocytes with HCMECs and/or HNDFBs.
Construction of scaffold-free vascularized cardiac graft patches
We assembled 1.4 Â 10 4 spheroids to create single cardiac patches. Each spheroid contained 1,000 cells, and the percentage of the cell types in the individual spheroids was 70% for RNVCMs, 15% for HCMECs, and 15% for HNDFBs. These ratios were determined in the experiments described in the Results section.
The detailed procedure used to create these patches was as follows. A cell suspension with 1.4 Â 10 7 cells containing RNVCMs, HCMECs, and HNDFBs at the above-mentioned percentages was plated into a low-attachment dish equipped with 1.4 Â 10 4 wells (Asahi Glass, Tokyo, Japan). After 1 day of cultivation, 1.4 Â 10 4 spheroids with a diameter of 100 μm were obtained, and the collected cardiac tissue spheroids were plated in low-attachment 100-mm dishes (Sumitomo Bakelite). The spheroids were arranged on the plate in the desired shape by gently rotating the dish several times ( Figure 6B ). Within 24 hours, the cardiac spheroids self-organized to form cardiac patch grafts under static conditions.
Live cell tracing of RNVCMs, HCMECs and HNDFBs
RNVCMs, HCMECs, and HNDFBs were stained green, red, and blue, respectively, using the Cell Tracker fluorescent probe (Molecular Probes Inc), following the manufacturer's instructions. The stained and suspended cells were mixed and plated to form cardiac spheroids in 96-well plates, and morphologic images and the degree of selforganization of the cardiac tissue spheroids were evaluated.
Macroscopic and microscopic analysis of the cardiac spheroids and cardiac grafts
Macroscopic images of the cardiac grafts were obtained using a HDR-CX720 digital camera (Sony). Phase-contrast and fluorescence images and motion videos were obtained using a BZ-9000 fluorescence microscope (Keyence, Osaka, Japan), and a Axiovert 40 CFL light microscope (Carl Zeiss). For cross-sectional observations, the grafts were fixed with 10% formalin, embedded in paraffin, and sectioned into 7-mm slices. Hematoxylin and eosin staining was performed according to standard methods, and the images were photographed with a BZ-9000 light microscope (Keyence). The contractibility of the cardiac spheroids and grafts was recorded using the BZ-9000 microscope imaging system. A motion analysis and measurements of the fractional shortening of the cardiac grafts were performed using the VW-9000 motion analysis software program (Keyence).
Cardiac graft transplantation into nude rats
F344 athymic rats (200-250 g; CLEA, Tokyo, Japan) were anesthetized with inhaled isoflurane, followed by the intraperitoneal administration of ketamine (75 mg/kg) and xylazine (10 mg/kg). The animals were subsequently intubated and mechanically ventilated with a rodent ventilator. The hearts were exposed via left thoracotomy, and the cardiac patch grafts were transplanted on the anterior wall of the left ventricle.
Results
The addition of fibroblasts and endothelial cells augmented cardiac spheroid formation
The time course of spheroid formation with cardiomyocytes (1,000 NRVCMs) is shown in Figure 2 (column A). Within 48 hours, the NRVCMs spontaneously aggregated to form contractile cardiac spheroids. We then examined the effects of adding endothelial cells (30%: Figure 2 
The addition of endothelial cells to cardiac spheroids promoted angiogenesis
To visualize the in vitro self-organization and vascularization of the cardiac tissue spheroids, we used a fluorescent cell tracker for live cell tracking during the formation of cardiac tissue spheroids. Cardiomyocytes were stained green, endothelial cells were stained red, and fibroblasts were stained blue. A mixture of these cells was suspended and cultured under the proper conditions to form cardiac tissue spheroids. After 2 days of cultivation, the cardiac spheroids were photographed with a fluorescent microscope. Figure 3 shows the photographs of 2-day-old contractile cardiac tissue spheroids. Figure 3C demonstrates the distribution of endothelial cells stained with the red cell tracker. Interestingly, microvascular channel and network formation was observed.
Pre-vascularized cardiac spheroids were assembled to form further scale contractile tissue Four 2-day-old cardiac spheroids were stained with the 3-color cell tracker probes described above and assembled. The 4 cardiac spheroids self-assembled with each other ( Figure 5 ). Remarkably, vascularization was confirmed within the cardiac spheroids. Of note, the vascularization was remodeled to be distributed near the outer surface of the newly assembled constructs.
Relationship between the proportion of cardiomyocytes within the cardiac spheroids and contractile capabilities To confirm the relationship between the proportion of cardiomyocytes and the contractile activity, we prepared 4 types of 2-day-old cardiac tissue spheroids containing cardiomyocytes at percentages of 100%, 70%, 50%, 30%, and 0%, respectively (n ¼ 12). The contraction of each type of spheroid was recorded for 10 seconds using video microscopy, and the fractional shortening (FS) was calculated by measuring the maximum and minimum distances between the 2 orthogonal axes in the cardiac tissue spheroids (Video 1, available on the jhltonline.org Web site). The mean FS for each type of spheroid is shown in Figure 5E . The proportion of cardiomyocytes within the cardiac tissue spheroids was directly proportional to the FS.
Fabrication of large-scale cardiac patch grafts with a microvascular network
For large-scale scaffold-free tissue engineering, approximately 1.4 Â 10 4 cardiac spheroids were replated in low-attachment 100-mm dishes and assembled to form round patch-like shapes under the floating culture conditions ( Figure 6A ). The process of fusion was photographed at 3, 12, and 24 hours of culture ( Figure 6D-F) . Within 24 hours, the spheroids had fused with each other, ultimately producing a large and contractile cardiac graft ( Figure 6C ). The mean diameter of the round cardiac graft was 9.4 Ϯ 0.6 mm (n ¼ 6), and the mean beating rate was 52 Ϯ 17 beats/min (n ¼ 5).
Figure 4
Time-lapse images of the assembly of the vascularized cardiac tissue spheroids.
To confirm the presence of the vascular network, RNVCMs and HCMECs were pre-stained using green and red fluorescent cell trackers, respectively. The stained cardiac spheroids were assembled to form a cardiac graft according to the procedure described above (n ¼ 3). Figure 6H indicates the appearance of the endothelial cells within the engineered grafts, and Figure 6K shows merged images. Microvascular channels and networks can be clearly seen within the grafts, and the grafts contracted synchronously (Videos 2 and 3, available on the jhltonline.org Web site).
Transplantation of cardiac grafts into the native heart in the nude rats
Large-scale cardiac grafts were transplanted onto the surface of the left ventricle in the nude rats via left subcostal thoracotomy under mechanical ventilation (n ¼ 5).
To avoid graft migration, anchor sutures using 7-0 polypropylene were placed on the surface of the nude rat heart ( Figure 7A ). The transplanted cardiac grafts were 
Discussion
In this study, we aimed to fabricate and transplant scaffoldfree, contractile vascularized engineered cardiac tissue grafts that could be used for clinical applications. To date, several studies using effective cell source injection techniques to restore the function of the damaged heart have been reported. 10 Furthermore, several recent studies have investigated the development of tissue engineering with the goal of further improving function of the damaged heart.
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Although these studies reported improvements in the heart function and degree of cell viability, there are several limitations and disadvantages, including excessive cell death, poor retention, inconsistent graft sizes, low cell density, immunogenicity, and the formation of toxic degradation products. [5] [6] [7] To overcome these disadvantages, we focused on spheroid culture, a known simple 3-D scaffold-free culture method. Halbert et al 12 reported that dissected rat neonate cardiomyocytes are capable of forming 3-D beating cell aggregates. Kelm et al 8 demonstrated that such cardiomyocyte aggregates not only contract synchronously but also have a similar intermicrotissue superstructure, retaining key cardiomyocytespecific cell qualities with a sophisticated extracellular matrix. Garzoni et al 13 reported that coculture of the cell aggregates with human umbilical cord endothelial cells produced vascular structures within the cardiac spheroids, followed by angiogenic sprouting into the spheroids. Furthermore, the cocultured cardiac spheroids showed improved cell viability.
In the current study, we also found fibroblasts were an important source of cells constituting myocardial tissue.
Most references cite the heart as being composed of 30% myocytes and 70% non-myocytes. The remaining nonmyocytes are mostly fibroblasts, which play essential roles in the myocardial function, particularly the synthesis and remodeling of the extracellular matrix. 14, 15 As described in this study, fibroblasts accelerate the process of cell aggregation, and coculture with endothelial cells results in enhanced vasculogenesis, with the formation of new blood vessels organized in a reticular pattern. According to that review article, cardiac myocytes occupy approximately 75% of the normal myocardial tissue volume. 14 In the present study, we decided to use cardiac spheroids containing 70% cardiomyocytes, 15% fibroblasts, and 15% endothelial cells. Although our results showed that a spheroid with 100% cardiomyocyte demonstrated the best mechanical performance (Figure 5 ), the addition of fibroblasts and/or endothelial cells promoted rapid self-organization of the cells to form spheroids (Figure 2) . We thus considered that a high ratio of cardiomyocytes with a small amount of fibroblasts and/or endothelial cells was preferable. Fortunately, the ratio used in our study achieved the successful fabrication of contractile cardiac tissue grafts, and the vascularized cardiac spheroids spontaneously assembled to form further largescale contractile cardiac grafts. Despite the aforementioned results, further studies are warranted to determine the optimal cell ratio for this strategy.
Our procedure has certain unique advantages that make it more robust than other procedures, including:
1. The resulting tissue grafts contain no biodegradable solid scaffolds. This scaffold-free technology reduces the incidence of inflammatory response-related toxic events and the risk of infection introduced by classic soluble scaffolds. 2. The tissue spheroids can be combined using several cell sources, including cardiomyocytes, endothelial cells, fibroblasts, mesenchymal progenitor cells, smooth muscle cells, and so on. These cell sources are considered to be certain "materials," and the proper combination and proportions of cells is required to generate characteristic tissue spheroids. Several reports have suggested that coculturing these different types of cells promotes cell maturation, development, and vasculogenesis and improves cell viability. [13] [14] [15] [16] [17] [18] [19] [20] 3. Scaffold-free tissue engineering using spheroids allows the spheroids to be handled, and when placed closely, to fuse into certain shapes.
Recent studies have reported the development of a robotic system for novel 3-D tissue engineering using layer-by-layer additive robotic biofabrication using tissue spheroids. 16, 17 The combined use of our cocultured spheroids and these novel biofabrication technologies may make it possible to fabricate natural functional human tissues and entire organs.
Although we have not succeeded in fabricating thicker myocardial tissue in vitro, we speculate that the approach of using a spheroid with mixed cell sources promotes vascularization due to a rich extracellular matrix. We expect that sheets with rich vasculature can be realized by determining the optimal cell number, cell ratio, configuration of the 3-D layer, and a refinement of the bioreactor. We summarized the advantages and disadvantages of the spheroid-based approach vs the scaffold-based approach in Table 1 .
Yamanaka et al 21, 22 recently established human and mouse-induced pluripotent stem cells. Pluripotent stem cells are able to differentiate into various cell types from all 3 germ layers both in vitro and in vivo, and many protocols have been developed to force these dedifferentiated cells to generate cardiomyocytes, endothelial cells, and mural cells. [23] [24] [25] In the near future, these emerging technologies may help to create autologous large-scale heart tissue grafts suitable for various clinical applications.
There are several limitations associated with this study: First, we used rat cardiomyocytes and a rat transplantation model. Data for large animals and primates are needed before the clinical applicability of this technique can be confirmed, and data using human cell sources are also needed. (A) Before transplantation of the cardiac tissue graft into the nude rat heart. (B) The cardiac tissue graft was located on the surface of the rat heart. (C) Explanted heart on day 7. Hematoxylin and eosin-stained sections of the (D) explanted heart and (E) graft.
Second, the accumulation of findings regarding the therapeutic effects of our technology for disease models, such as those involving myocardial infarction and/or heart failure, would also be helpful.
Third, functional analyses for in vivo models (e.g., to assesses arrhythmia, synchronicity and the effects of mechanical enforcement, etc), as well as quantitative data for the mechanical functions and degree of cell viability in vivo are also needed.
Finally, although we were able to show that the cardiac patch was alive and vascularized after transplantation, we have yet to show that the patch was synchronically contracting with the native heart. In addition, whether the cardiac patch was incorporated into the native heart is not shown. Further studies to improve our strategies would be helpful for increasing the scale of our procedure.
In conclusion, we consider the application of our scaffold-free 3-D tissue engineering technology for cardiac regeneration therapy is feasible and expect that this technology will become a promising tool for the treatment of end-stage heart failure.
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